Kymera Therapeutics to Participate in Upcoming February Investor Conferences
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has announced its participation in two major investor conferences in February 2025.
The company will engage in fireside chats at the Guggenheim SMID Cap Biotechnology Conference in New York on February 6 at 10:00 a.m. ET, and the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event, on February 11 at 11:20 a.m. ET.
Live webcasts of both presentations will be accessible through the Investors section under "News and Events" on Kymera's website (www.kymeratx.com). Recordings will be archived and available for viewing after the events.
Kymera Therapeutics (NASDAQ: KYMR), una compagnia biofarmaceutica in fase clinica focalizzata sullo sviluppo di medicinali degradatori a piccole molecole orali, ha annunciato la sua partecipazione a due importanti conferenze per investitori a febbraio 2025.
L'azienda parteciperà a chiacchierate informali alla Guggenheim SMID Cap Biotechnology Conference a New York il 6 febbraio alle 10:00 ET, e alla Oppenheimer 35th Annual Healthcare Life Sciences Conference, un evento virtuale, l'11 febbraio alle 11:20 ET.
Le dirette web di entrambe le presentazioni saranno accessibili attraverso la sezione Investitori sotto
Kymera Therapeutics (NASDAQ: KYMR), una empresa biofarmacéutica en etapa clínica enfocada en desarrollar medicamentos degradadores de pequeñas moléculas orales, ha anunciado su participación en dos importantes conferencias de inversores en febrero de 2025.
La compañía participará en charlas informales en la Guggenheim SMID Cap Biotechnology Conference en Nueva York el 6 de febrero a las 10:00 a.m. ET, y en la Oppenheimer 35th Annual Healthcare Life Sciences Conference, un evento virtual, el 11 de febrero a las 11:20 a.m. ET.
Las transmisiones en vivo de ambas presentaciones estarán disponibles en la sección de Inversores bajo
Kymera Therapeutics (NASDAQ: KYMR)는 경구용 소분자 분해제 의약품 개발에 주력하는 임상 단계의 생물 의약품 회사로, 2025년 2월 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다.
회사는 2월 6일 오전 10시 ET에 뉴욕에서 열리는 Guggenheim SMID Cap Biotechnology Conference와 2월 11일 오전 11시 20분 ET에 열리는 가상 이벤트인 Oppenheimer 35th Annual Healthcare Life Sciences Conference에서 대담에 참여할 예정입니다.
두 프레젠테이션의 실시간 웹캐스트는 Kymera의 웹사이트(www.kymeratx.com)의 투자자 섹션에서
Kymera Therapeutics (NASDAQ: KYMR), une entreprise biopharmaceutique en phase clinique axée sur le développement de médicaments dégradants à petites molécules orales, a annoncé sa participation à deux grandes conférences d'investisseurs en février 2025.
L'entreprise participera à des discussions informelles lors de la Guggenheim SMID Cap Biotechnology Conference à New York le 6 février à 10h00 ET, et à la Oppenheimer 35th Annual Healthcare Life Sciences Conference, un événement virtuel, le 11 février à 11h20 ET.
Des webcasts en direct des deux présentations seront accessibles dans la section Investisseurs sous
Kymera Therapeutics (NASDAQ: KYMR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von oralen niedermolekularen Abbau-Medikamenten konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Februar 2025 angekündigt.
Das Unternehmen wird an informellen Gesprächen auf der Guggenheim SMID Cap Biotechnology Conference in New York am 6. Februar um 10:00 Uhr ET und an der Oppenheimer 35th Annual Healthcare Life Sciences Conference, einer virtuellen Veranstaltung, am 11. Februar um 11:20 Uhr ET teilnehmen.
Live-Streams beider Präsentationen sind über den Investorenbereich unter
- None.
- None.
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
- Guggenheim SMID Cap Biotechnology Conference in New York, NY on February 6 at 10:00 a.m. ET; and
- Oppenheimer 35th Annual Healthcare Life Sciences Conference held virtually on February 11 at 11:20 a.m. ET.
Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
When and where will Kymera Therapeutics (KYMR) present at the Guggenheim SMID Cap Conference?
What time is KYMR's presentation at the Oppenheimer Healthcare Conference?
How can investors access Kymera Therapeutics' (KYMR) February 2025 conference presentations?
Will recordings of KYMR's February 2025 investor presentations be available?
